PRPH vs. CLNN, VTVT, KLRS, IMMX, IZTC, ASRT, EQ, UNCY, VXRT, and XBIT
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Clene (CLNN), vTv Therapeutics (VTVT), Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), Assertio (ASRT), Equillium (EQ), Unicycive Therapeutics (UNCY), Vaxart (VXRT), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.
ProPhase Labs vs. Its Competitors
Clene (NASDAQ:CLNN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Clene presently has a consensus target price of $32.60, suggesting a potential upside of 278.19%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than ProPhase Labs.
23.3% of Clene shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 35.3% of Clene shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Clene has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500.
Clene has higher earnings, but lower revenue than ProPhase Labs. Clene is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
ProPhase Labs has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat ProPhase Labs' return on equity.
In the previous week, Clene had 5 more articles in the media than ProPhase Labs. MarketBeat recorded 6 mentions for Clene and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 1.53 beat Clene's score of 0.62 indicating that ProPhase Labs is being referred to more favorably in the news media.
Summary
Clene beats ProPhase Labs on 10 of the 16 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
This page (NASDAQ:PRPH) was last updated on 10/21/2025 by MarketBeat.com Staff
Free PRPH Stock Alerts